Phase 3 Clinical Trials With Primary Completion Dates in August 2022
This is a list of Phase 3 trials with primary completion dates in August 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| BVNRY | Bavarian Nordic A/S | 2022-08-01 | Phase 3 | NCT02977715 | IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo |
| INO | Inovio Pharmaceuticals, Inc. | 2022-08-01 | Phase 3 | NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) |
| KRTX | Karuna Therapeutics, Inc. | 2022-08-01 | Phase 3 | NCT04738123 | A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) |
| VTGN | VistaGen Therapeutics, Inc. | 2022-08-01 | Phase 3 | NCT05011396 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 |